Citadel Advisors’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-35,166
| Closed | -$141K | – | 13409 |
|
|
2025
Q2 | $141K | Sell |
35,166
-144,849
| -80% | -$359K | ﹤0.01% | 11013 |
|
|
2025
Q1 | $164K | Sell |
180,015
-436,894
| -71% | -$606K | ﹤0.01% | 10730 |
|
|
2024
Q4 | $1.71M | Buy |
616,909
+567,349
| +1,145% | +$2.16M | ﹤0.01% | 5959 |
|
|
2024
Q3 | $259K | Buy |
49,560
+23,665
| +91% | +$123K | ﹤0.01% | 9601 |
|
|
2024
Q2 | $115K | Sell |
25,895
-66,823
| -72% | -$324K | ﹤0.01% | 10710 |
|
|
2024
Q1 | $710K | Sell |
92,718
-66,745
| -42% | -$366K | ﹤0.01% | 7641 |
|
|
2023
Q4 | $679K | Buy |
159,463
+25,453
| +19% | +$90.4K | ﹤0.01% | 7455 |
|
|
2023
Q3 | $563K | Sell |
134,010
-11,590
| -8% | -$59K | ﹤0.01% | 7809 |
|
|
2023
Q2 | $811K | Sell |
145,600
-648,223
| -82% | -$3.83M | ﹤0.01% | 6895 |
|
|
2023
Q1 | $4.55M | Buy |
+793,823
| New | +$2.1M | ﹤0.01% | 3970 |
|
|
2022
Q4 | – | Sell |
-110,648
| Closed | -$297K | – | 15155 |
|
|
2022
Q3 | $297K | Sell |
110,648
-10,179
| -8% | -$36.8K | ﹤0.01% | 9606 |
|
|
2022
Q2 | $577K | Buy |
120,827
+22,530
| +23% | +$98K | ﹤0.01% | 8316 |
|
|
2022
Q1 | $402K | Sell |
98,297
-8,681
| -8% | -$51.1K | ﹤0.01% | 9887 |
|
|
2021
Q4 | $729K | Buy |
106,978
+12,512
| +13% | +$108K | ﹤0.01% | 8738 |
|
|
2021
Q3 | $1.09M | Sell |
94,466
-76,600
| -45% | -$1.19M | ﹤0.01% | 7908 |
|
|
2021
Q2 | $2.92M | Sell |
171,066
-69,335
| -29% | -$1.21M | ﹤0.01% | 5676 |
|
|
2021
Q1 | $4.76M | Sell |
240,401
-12,141
| -5% | -$268K | ﹤0.01% | 4364 |
|
|
2020
Q4 | $5.21M | Buy |
252,542
+11,464
| +5% | +$273K | ﹤0.01% | 3605 |
|
|
2020
Q3 | $6.34M | Buy |
+241,078
| New | +$5.99M | ﹤0.01% | 2835 |
|
Citadel Advisors's INZY Position: Q3 2025 in Review
Citadel Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 35,166 shares — an estimated $141K sold.
Citadel Advisors first reported a position in INZY in Q3 2020 and held it in 19 quarters. The position peaked at $6.34M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Citadel Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 35,166 Inozyme Pharma shares in Q3 2025, an estimated $141K.
- Citadel Advisors first reported a position in Inozyme Pharma in Q3 2020 and held it in 19 quarters.
- Citadel Advisors's Inozyme Pharma position peaked at $6.34M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.